2. Academic Validation
  3. Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

  • NPJ Parkinsons Dis. 2024 Mar 14;10(1):59. doi: 10.1038/s41531-024-00657-7.
Michel Alexander Steiner 1
Affiliations

Affiliation

  • 1 Idorsia Pharmaceuticals Ltd, CNS Pharmacology, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. michel.steiner@idorsia.com.
PMID: 38486022 DOI: 10.1038/s41531-024-00657-7
Figures
Products